Machine learning-based high-benefit approach versus traditional high-risk approach in statin therapy: the Shizuoka Kokuho database study.

Journal: Scientific reports
Published Date:

Abstract

Statins are widely prescribed for the primary prevention of cardiovascular diseases, yet individual responses vary, necessitating personalized treatment strategies. Conventional approaches prioritize treating high-risk patients, but advancements in machine learning now enable the estimation of conditional average treatment effects (CATE), offering opportunities to enhance treatment effectiveness. This study utilized the Shizuoka Kokuho Database to investigate heterogeneity in statin treatment effects. A 1:1 propensity score-matched cohort design was employed to evaluate the effect of statins in preventing a composite outcome, cardiovasuclar and cerebrovascular events and all-cause mortality. CATE was estimated using the causal forest model, an advanced ensemble machine learning technique. The effectiveness of a novel high-benefit treatment approach was compared with the traditional high-risk strategy. The propensity score-matched cohort included 8,792 individuals (mean age 67.4 years, 68.6% women). The causal forest model identified substantial heterogeneity in treatment effects. The high-benefit approach achieved a number needed to treat (NNT) of 15.1 (95% confidence interval [CI]: 9.4-23.4), significantly outperforming the high-risk approach (NNT: 29.5, 95% CI: 17.2-235.3). These findings demonstrate that leveraging machine learning to estimate CATE can enhance statin therapy by personalizing treatment, minimizing unnecessary medication, and improving population health outcomes.

Authors

  • Ryo Watanabe
    Department of Radiology, Hospital of University of Occupational and Environmental Health, Iseigaoka 1-1, Yahatanishi-ku, Kitakyushu-shi, Fukuoka 807-8555, Japan.
  • Eiji Nakatani
    Graduate School of Public Health, Shizuoka Graduate University of Public Health, 4-27-2 Kitaando, Aoi-ku, Shizuoka, 420-0881, Japan. nakatani.eiji.int@gmail.com.
  • Hideaki Kaneda
    Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
  • Daito Funaki
    Graduate School of Public Health, Shizuoka Graduate University of Public Health, 4-27-2 Kitaando, Aoi-ku, Shizuoka, 420-0881, Japan.
  • Yohei Sobukawa
    Graduate School of Public Health, Shizuoka Graduate University of Public Health, 4-27-2 Kitaando, Aoi-ku, Shizuoka, 420-0881, Japan.
  • Yoshihiro Tanaka
    Graduate School of Public Health, Shizuoka Graduate University of Public Health, 4-27-2 Kitaando, Aoi-ku, Shizuoka, 420-0881, Japan.
  • Nagato Kuriyama
    Graduate School of Public Health, Shizuoka Graduate University of Public Health, 4-27-2 Kitaando, Aoi-ku, Shizuoka, 420-0881, Japan.
  • Masato Takeuchi
    Graduate School of Public Health, Shizuoka Graduate University of Public Health, 4-27-2 Kitaando, Aoi-ku, Shizuoka, 420-0881, Japan.
  • Akira Sugawara
    Graduate School of Public Health, Shizuoka Graduate University of Public Health, 4-27-2 Kitaando, Aoi-ku, Shizuoka, 420-0881, Japan. asugawara@s-sph.ac.jp.